Clinical trial · Observational
ADN Fœtal Circulant, Grossesse et Pathologies Malignes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In France in 2021, 90% of pregnant women chose to undergo screening for Trisomy 21, and 128,958 women benefited from a fetal aneuploidy screening test based on the analysis of cell-free DNA (cfDNA) in maternal blood. At the beginning of its use, this analysis was limited to screening for Trisomy 21, but it now allows the study of all chromosomes (expanded screening). More than half of fetal chromosomal abnormality screenings are expanded tests, and this practice continues to grow. In oncology, circulating tumor DNA (ctDNA) is studied for the detection, prognostic evaluation, and monitoring of the effectiveness of certain treatments. The high-throughput sequencing tools used for aneuploidy screening during pregnancy are likely to detect malignant diseases. Cancer is associated with pregnancy in 1 in 1,000 to 1 in 1,500 pregnant women, and the spread of expanded aneuploidy screening during pregnancy makes it possible to detect maternal cancers, including at infraclinical stages. This study will therefore help manage situations involving difficult-to-interpret results, such as suspected maternal cancer. It will make it possible to identify specific chromosomal abnormalities to be tested, which could potentially be included in future recommendations. In a second stage, it could contribute to harmonizing the practices of laboratory specialists performing fetal chromosomal abnormality screening using cfDNA.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Femmes Enceintes | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of a sample | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary outcome measure is the presence of a chromosomal profile suggestive of a malignant disease (i.e., classification with a moderate or high probability).
- timeFrame
- 32 months
- description
- "The primary outcome measure is the presence of a chromosomal profile suggestive of a malignant disease (i.e., classification with a moderate or high probability). 1. Low probability: Chromosomal profile not suggestive of maternal malignant disease (no abnormality\* or 1 to 2 abnormalities suggestive of a translocation derivative or an inversion recombinant). 2. Moderate probability: Chromosomal profile moderately suggestive of maternal malignant disease (2 abnormalities\*). 3. High probability: Chromosomal profile strongly suggestive of maternal malignant disease (3 or more abnormalities\*). * An abnormality is defined as a trisomy, a monosomy, or a segmental imbalance greater than 7 Mb."
Secondary outcomes (3)
- measure
- The type of tissue of origin involved in the development of the malignant disease.
- timeFrame
- 32 MONTHS
- measure
- The stage of cancer development (according to the classification used for each type of cancer considered, e.g., TNM, FIGO, etc.)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Inclusion Criteria (Cases): * Adult patient (≥18 years old); * Pregnant patient with a cancer known prior to pregnancy or diagnosed during pregnancy; * Pregnancy at a gestational age \> 10 weeks of amenorrhea at the time of inclusion; * Patient informed and having signed the informed consent form to participate in the study. Exclusion Criteria: * Multiple pregnancy; * Patient with a history of organ transplantation; Patient having received an allogeneic stem cell transplant; * Known maternal mosaic chromosomal abnormality and copy number variation (CNV); * Patient presenting with one or more known uterine fibroids at the time of inclusion; * Technical inability to conduct a teleconsultation via a secure video connection and to complete an electronic signature.
References
Publications (0)
Data not yet available